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Abstract
Background: The dissemination of  extended-spectrum β-lactamase (ESBL)-producing bacteria presented a great concern 
worldwide. Gram-negative organisms such as Escherichia coli and Klebsiella pneumoniae are the most frequently isolated pathogens 
responsible for nosocomial infections.
Objectives: The aim of  this study was to investigate and to follow the emergence of  resistance and the characterization of  
Extended-Spectrum Beta-Lactamases (ESBL) among broad-spectrum beta-lactam-Escherichia coli clinical isolates recovered from 
the military hospital and Habib Thameur hospital in Tunisia.
Methods: A total of  113 E.coli isolates obtained during the period 2004 through 2012 showed a significant degree of  multi-resis-
tance. Among these strains, the double-disk synergy test confirmed the ESBL phenotype in 46 isolates. These included 32(70%) 
strains from Hospital A and 14(30%) from Hospital B.
Results: The ESBL was identified as CTX-M-15. The ESBL resistance was transferred by a 60 kb plasmid CTXM-15-produc-
ing isolates were unrelated according to the PFGE analysis and characterization of  the regions surrounding the blaCTX-M-15 
showed the ISEcp1 elements located in the upstream region of  the bla gene and 20 of  them truncated by IS26.
Conclusion: ESBL producing E. coli strains are a serious threat in the community in Tunisia and we should take into consider-
ation any possible spread of  such epidemiological resistance.
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Introduction
The production of  extended-spectrum β-lactamases con-
tinues to be the important cause of  resistance among 
gram negative bacteria.
The TEM- and SHV- are the first ESBLs type, mutant 
derivatives of  established plasmid-mediated β-lactamases 
, however  , a novel type of  plasmid mediated ESBLs, 
the CTX-M enzymes, cefotaximases, emerged worldwide 
in the last decade, and preferentially hydrolyze cefotax-
ime over ceftazidime and are inhibited by clavulanic acid, 
sulbactam, and tazobactam1 were reported in the second 
half  of  the 1980s classified in Ambler class A and in 
group 2be of  the Bush, Jacoby and Medeiros classifica-
tion2.
More than 65 CTX-M β-lactamases were revealed world-
wide. The phylogenic study clustered them in five major 
groups: CTXM 1,-2, -8, -9, and -25 groups3-5 .
 
The number of  reports studing the CTX-M variants con-
tinue to increase,CTX-M-28 enzyme was recently report-
ed in Tunisa6,7.
CTX-M-9, first described in 1994 in Spain8, Guyana and 
the United Kingdom9 also in Tunisa10.
Also, in 2006, Boyd et al mention the first report of  
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CTX-M-16 type-producing Enterobacteriaceae in Tunisia 
and in Africa11.
Another variant of  CTX-M type, CTX-M-8 was detected 
in cefotaxime-resistant Proteus mirabilis strain in associa-
tion with a plasmid mediated AmpC lactamase12.
CTX-M-15 is the most prevalent ß-lactamase detect-
ed amongst the ESBL-positive K. pneumoniae and E. coli 
strains derived from CTX-M-3 by a substitution of  Asp-
240-Gly which increases its catalytic efficiency against 
ceftazidime13,14  first described in 200115,16 
Many reports have documented the emergence of  
CTX-M gene9, and the first report of  the CTX-M-15 in 
Tunisia was cited in the Charles Nicolle Hospital in 1984 
and it was described in various studies in Tunisia includ-
ing that of  coque et al, the gene has been found in E. coli 
strains  in a Tunisian Hospital17, France18, and Central Af-
rican Republic19-25 .91% of  the ESBL-producing isolates 
carried blaCTX-M-15 genes21.
The production of  CTX-M enzymes is an emerging phe-
nomenon that has been called ‘the CTX-M pandemic’16.
 
The insertion sequence ISEcp1 was found to be involved 
in the mobility of  blaCTX-M,was located upstream the 
bla CTX-M-27 gene e in  a neonatal ward of  the mater-
nity department of  Farhat Hached Hospital, Sousse26 .It 
has been found also upstream the CTX-M-14 producing 
E. coli isolated from hospitalized patients in a university 
Hospital of  Tunisia27., and upstream the CTX-M-15 gene 
in Proteus mirabilis and Morganella morganii isolated at the 
Military Hospital of  Tunis24.
ISEcp1 was located upstream of  the blaCTX-M gene on 
E. coli isolates from food samples28.
CTX-M genes may spread through clonal dissemination 
or horizontal gene transfer19.
Methods
Bacterial strain
These clinical strains were isolated from samples collect-
ed in different wards, including the emergency (25, 86 %), 
reanimation (16.07 %), hemodialysis (4.56 %), neonatal 
(4.24 %), pediatrics (4.39 %), gastroenterology (13.32 %), 
external (12.56 %) and urology (19 %).
 
68% of  strains were from urine, 17.8% from blood cul-
ture and 14.2% from Pus.
 
All the isolates were identified by the Vitek automat-
ed system (bioMérieux, Vitek 32) and API 20E system 
(bioMérieux, Marcy l’Etoile, France).
 
E. coli DH5a (recA1, F_, end A1, gyrA96, thi-1, hsdR17, 
rK_, mK+, supE44, relA1, DlacU69, F80lazDM15) and 
E. coli HB101 (F_, D(gpt-proA) 62, leuB6, supE44, ara-
14, galK2, lac Y1, D(mcrc-mrr), rps, L26, Xyl-rmtl 1, 
thi-1, IncFI, rec AB, strr), were used respectively for the 
transformation and conjugation experiments.
                                               
Antimicrobial susceptibility and synergy testing
Routine antibiograms were determined by the disk diffu-
sion method on Mueller–Hinton agar (MH, Diagnostics 
Pasteur) using susceptibility breakpoints as recommend-
ed by the Clinical and Laboratory Standards Institute 
(CLSI)29. 
 
The double-disk synergy test was used to detect the 
ESBL production as previously described30,24 by using 
amoxicillin–clavulanate against cefotaxime, ceftriaxone, 
ceftazidime and aztreonam.
Minimum inhibitory concentrations (MICs) of  selected 
anti-microbial agents were determined by using the dilu-
tion method on Mueller–Hinton agar according to CLSI 
guidelines29.
 
Table 1 shows MICs (µg/mL) of  various antimicrobial 
agents obtained for the clinical isolate E. coli, transconju-
gant and transformant, and the E. coli recipients.
CTX, cefotaxime; CRO, ceftriaxone; CAZ, ceftazidime; 
ATM, aztreonam; TIC, ticarcillin; STR, streptomycin; 
IMP, imipenem; ERT, ertapenem; CHL, chloramphen-
icol; TET, tetracycline; OFX, ofloxacin. NM, not mea-
sured.
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β-Lactamase extraction and isoelectric focusing
IEF was performed as described previously17,31, using a 
culture grown overnight at 37°C in Trypto-Caseine Soy 
broth (TCS). These exponentially growing bacteria were 
harvested at 17,400 _ g (Rotor F 0650, Bekman) and bac-
terial suspensions were prepared by sonication in UP 400 
S (dv. Hielscher, Germany) five times for 45 s each time.
Crude extract was centrifuged at 17,400 _ g (Universel 32 
R, Hettich) for 15 min at 4°C.
The supernatant of  the sonicate was subjected to isoelec-
tric focusing on ampholine polyacrylamide gel with a pH 
range of  3-10 at a voltage range of  100-300,  at 4oC in a 
111Mini IEF Cell (Bio-Rad). TEM-1 (pI 5.4), TEM-2 (pI 
5.6), TEM-3 (pI 6.3), SHV-1 (pI 7.6) and SHV-12 (pI 8.2) 
were used as pI markers.
β-lactamase activities were revealed by iodemetric method 
using benzylpenicillin to 1 mM and cefotaxime (3 mM) as 
substrates in phosphate buffer (25 mM; pH 7).
β-Lactamase assay
Hydrolytic activities of  crude extracts for β-lactam antibi-
otics were determined by the spectrophotometric meth-
od at the wave length of  maximal absorbance for the 
β-lactam ring of  each antibiotic.32
The decrease in absorbance of  the antibiotics at an ap-
propriate concentration was measured in a temperature 
controlled spectrophotometer (Varian R CARY 50 Bio 
UV-visible) at 37°C.
Specific activity is calculated on depending of  Ross and 
O’Callaghan equation in 197533
 
Effect of  inhibitors (IC50 determination)
Crude enzyme extract was incubated with clavulanic acid 
and sulbactam increasing concentrations. EDTA was 
used at a fixed concentration of  1 mM. Residuals β-lac-
tamases activities were determined by the spectropho-
tometric method using cephalothin 1 mM as substrate. 
The inhibitor concentration required to inhibit 50% of  
enzyme activity was determined graphically (IC50)34. 
 
Analysis of  plasmids and transfer of  resistance
Plasmid DNA was extracted with the alkaline lysis meth-
od, as described by Sambrook et al35.
Conjugation experiments were carried out with E. coli 
HB101, as previously described7,24. (31; 9;3;4).
The transconjugants were selected on LB agar supple-
mented with streptomycin (100 μg/ml) and ampicillin 
(100 μg/ml).
 
Transformation experiments were carried out by using E. 
coli DH5α as the recipient as previously described31,36. 
Transformants were selected on Luria-Bertani medium 
agar plates supplemented with ampicillin (100 mg/ml).
Transformants were subjected to DDST to confirm the 
presence of  ESBL genes and were examined for co-trans-
fer of  other antibiotic resistance determinants present in 
the donor clinical isolates by disk diffusion.
 
Characterization of  the resistance genes using PCR 
method and sequencing
Primers used for amplification of  resistance genes, an-
nealing temperatures and predicted amplicon sizes are 
shown in Table 1. They were used to detect blaCTX-M, 
blaSHV, blaTEM and the sequences surrounding the bla 
CTX-M gene, ISEcp1and IS2637,38 also the aac(6’)-ib-cr 
gene.












CTX-M CTX-M-A 5’ TTT GCG ATG TGC AGT ACC 
AGT AA3’ 
  544 57°C (Edelstein et 
al., 2003) 
CTX-M-B 5’ CGA TAT CGT TGG TGG TGC 
ATA3’ 




SHV SHV-F 5’ ATTTGTCGCTTCTTTACTCGC3’ 861 55°C (Essack et al., 
2001) SHV-R 5’ TTTATGGCGTTACCTTTGACC’ 
ISEcp1 ISEcp1-A 5’GCAGGTCTTTTTCTGCTCC3’ 490 57 ᵒC Lartigue et al., 
2004) ISEcp1-B 5’ATTTCCGCAGCACCGTTTGC3’ 
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The DNA amplification programs consisted of  initial de-
naturation for 5 min at 94°C, followed by 30 cycles of  
denaturation for 30 s at 94°C, annealing temperatures 
differed according to the primer pair used and were for 
45 s at 57°C for the blaCTX-M and blaISEcp1; 55°C for 
blaTEM and blaSHV. Finally, the polymerization for 5 
min at 72°C.
PCR products were purified using QIAquick PCR Puri-
fication Kit (Qiagen, USA) and sequenced using the Big-
Dye Terminator v.3.1 Cycle Sequence Kit and ABI Prism 
310 automatic sequencer (Applied Biosystems, USA).
The nucleotide sequences were compared with those in-
cluded in the GenBank database using BLAST (http:/
www.ncbi.nlm.nih.gov/blast/).
 
Detection of  ISEcp1
PCR for ISEcp1 was used to examine the  region up-
stream of  the the blaCTX-M gene with the primers 
shown in Table 1.  An annealing temperature,57oC was 
used followed by sequencing of  the PCR product.
 
Typing of  isolates by MLST
Molecular typing was performed for one representative 
E. coli isolate by MLST by PCR amplification of  the seven 
housekeeping loci (adk, fumC, gyrB,icd, mdh, purA and 
recA).
The amplicon was sequenced and compared with the 
MLST database.(http://mlst.ucc.ie/mlst/dbs/Ecoli)39.
Molecular typing using Pulsed-field gel electropho-
resis (PFGE)
The epidemiological relationship of  CTX-M-15 positive 
strains was studied by PFGE using XbaI as restriction 
enzymes (Bio-Rad Laboratories, France).
Restriction fragments of  DNA were separated by electro-
phoresis which was performed in a 1.2% agarose gel on 
a CHEF DRIII apparatus (Bio-Rad Laboratories, Rich-
mond, CA, USA) with 6V/cm for 19 h at 14ºC with an 
initial switch time of  2.2 to 52.0 sec.
XbaI-digested DNA were compared visually based on 
differences in the number and mobility of  bands40.
Results
Studied strains show multidrug resistance phenotype with 
various antibiotics. They were  highly resistant to anti-
biotics  such as penicillins, cephalosporins, aminoglyco-
sides, quinolones and tetracycline, (MIC 512- 64µg/mL) 
whereas remained susceptible to imipinem (MIC <2µg/
ml) and meropenem (MIC <0,5µg/ml) (Table 2 ). Sim-
ilar results were observed with the transformants and 
transconjugants except with quinolones, phenicol and 
aminoglycosides, suggesting that this resistance could be 
in chromosome.
46 E. coli strains were phenotypically confirmed as ESBL 
with the double disc synergy showing a marked synergy 
between ceftazidime, céfotaxime, aztreonam, ceftriaxon-
eand amoxicillin–clavulanic acid on MH agar  plates as 
well as the transformants and transconjugants suggested 
the presence of  a class A ESBL.
Table 2:  MICs (µg/mL) of various antimicrobial agents obtained for the clinical isolate E. 













































































2 <2 <2 
  
Isolates Year of 
isolation 
Ward Specimen MIC (mg/l) 
Cefotaxime Ceftriaxon Ceftazidime Aztreonam Ticarcillin Streptomycin Imipenem ERT CHL Tetracyclin OFX 
E.coli 4836 2011 urology urine >512 >512 >512 >512 >512 128 <2 0 .5 128 64 64 
E. coli HB101 
X 





512 512 128 512 256 <2 0.5 32 64 128 
E. coli HB101                           _ <2 <2 <2 <2 8 2 <2 <2 <2 <2 <2 
E. 
coli DH5α/ E. 
coli 4836 
                      _ 512 512 16 512 >512 256 ≤0 .006 <0.5 8 4 <2 
E. coli DH5a                              _ <2 <2 <2 <2 <2 <2 ≤0 .006 <0.5 2 <2 <2 
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The resistance to expanded-spectrum cephalosporins 
was successfully transferred to a recipient strains, E. coli 
HB101 with the frequency of  transfer equivalent to 5× 
10-5 transconjugant/recipient and this indicated that the 
gene was plasmidic transferred with an estimated molec-
ular size of  60 kb of  the transferable plasmid.
 
An extended-spectrum β-lactamase band with a pI 8.6 
with cefotaxime as substrate was detected in the 46 ESBL 
strains (Figure 1), transformants and transconjugants.
Kinetics resuts showed that E. coli strains hydrolyze ben-
zylpenicillin, ticarcillin with a high level of  hydrolytic ac-
tivity, specific activities ranged between (8.77-6.67U/mg 
of  protein) and hydrolyze cephalosporins with a higher 
hydrolytic activity to cefotaxime (U/mg of  protein) (Ta-
ble 3).
Figure1: Isoelectric focusing (7%) with cefotaxime for 1mM as substrate of the 
E. coli strains 1-8: E. coli strains; pI: pI markers TEM-1 (pI 5.4), TEM-2 (pI 5.6), 
TEM-3 (pI 6.3), SHV-1 (pI 7.6) and SHV-12 (pI 8.2) 
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Table 3: Specific activities  β -lactamases of E. coli strain 4836 and its  transconjugant  (μmol of 
substrate hydrolyzed/min/mg of protein). 
  
Antibiotics E. coli 4836 E. coli HB101 X E. coli 4836 
Benzylpenicilli 8.77 2.63 
Ticarcillin 6.67 2.43 
Imipenem ND ND 
Cefoxitine 0.654 0.755 
Cefotaxime 5.16 2.55 
Ceftriaxone 0.239 0.192 
Ceftazidime 0 .16 0.116 
Aztreonam 0. 455 0.430 
Cefpirome 0.31 0.02 
ND: non detected. 
These enzymes are not inhibited by EDTA and are not 
defined as metallo-enzymes.  The analysis of  the IC50 
showed that the clavulanic acid with IC50 of  3.5 µM was 
the powerful inhibitor and categorized this enzyme to 
class A: serine active β-lactamases (Table 4).
PCR analyses confirmed the presence of  blaCTX-M-3- 
related genes in parental strain E. coli  4836, and transfor-
mant E. coli DH5α/ E.coli 4836 and transconjugant E. 
coli HB101 X,  E.coli 4836 indicating that this gene is lo-
cated on conjugative plasmid.Sequencing of  the deduced 
amino acid, followed by BLAST searches, and  confirmed 
blaCTX-M as blaCTX-M-15.
This enzyme  preferentially hydrolyzed cefotaxime over 
ceftazidime.
Table 4. Inhibitors effect of activities β-lactamases of E. coli 4836 strain (IC50) 
 
E. coli 4836 IC50 (µM) 
Clavulanic acid Sulbactam EDTA 
  3.5 14.7 - 
  
(–): without effect 
15 strains produced the quinolone resistance determi-
nants aac(6´)-Ib-cr whereas ISEcp1 sequence was found 
in CTX-M-15- producing isolates.
When using the specialized primers reversibly of  IS se-
quences (ISEcp1 and  the IS26) with blaCTX-M-15 prim-
ers, We came to the result that the ISEcp1 sequence was 
found upstream of  the blaCTX-M-15 gene.
On the other hand, IS26 transposase region was detected 
upstream of  the ISEcp1 sequence on 22 of  our studied 
E. coli isolates.
According to the MLST analysis of  one E. coli isolate, it 
showed that this belonged to ST 131, displayed specific 
O25 type (O 25b) and the E. coli isolate belonged to the 
B2 phylogenetic subgroup I.
PFGE  (Figure 2) showed that the 46 strains presented 
different profiles, and our studied strains were unrelated 
suggesting that the dissemination of  bla CTX-M-15gene 
among E. coli clinical strains due to horizontal transfer of  
multi- resistance or/and the genetic mobile element are 
responsible for the dissemination of  these gene.
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Discussion
Our study investigated the genetic environment of  blaC-
TX-M genes in fourty six Escherichia coli extended spec-
trum β-lactamase (ESBL)-positive isolates. Of  these 46 
strains,  10 E. coli isolates (24 %) produced  ß-lactamase 
activities with a varied isoelectric points (pIs) between 
5.5 and 8,6 (lane 1,5 and 6, Figure 1), they carried the 
blaTEM gene (9 from hospital A and 1 from hospital B). 
Sequencing of  PCR products of  this latter showed  that 
it corresponded  to the TEM-1.
9 of  the studied E. coli isolates (26 %) presented a basic 
pIs of  7.3 and 8.6 (lane 2,3,4,7 and 8, Figures 1). They 
carried the blaSHV gene (8 from hospital A and 1 from 
hospital B) and it corresponded to SHV-1 by sequencing.
The presence of  the insertion sequence ISEcp1upstream 
the gene in all the CTX-M-15 strain producers is a real 
concern which plays an important role of  the mobiliza-
tion of  this latter as has been reported in several stud-
ies16,41.
According to the MLST analysis of  one E. coli isolate, 
it showed that this belonged to ST 131, displays specif-
ic O25 type (O 25b) and the E. coli isolate belonged to 
the B2 phylogenetic subgroup I. This phylogroup B2 
ST131 is previously described on E.coli CTX-M produc-
ers responsible for the clonal diffusing of  the CTX-M-15 
gene41,42 and this isolate may belong to this clone.
The presence of  the blaCTX-M-15 encoding gene 
amongst unrelated strains argued for genetic transit of  
mobile elements amongst unrelated strains. Our study 
confirms that the CTX-M-15 gene is the most prevalent 
ESBL found in Tunisian hospitals and the association of  
the bla CTX-M-15 with the insertion sequence ISEcp1 
facilitates its dissemination.
In short with reference to our insightful study, we should 
control the emergence of  ESBL producing E. coli strains 
from hospitals environment   which in some cases lack 
both the efficient surveillance and cleaning services.
Figure 2. Pulsed-field gel electrophoresis (PFGE) of XbaI-digested genomic DNA 
of the E. coli isolates producing CTX M-15 (Lane 1-20)
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This finding is alarming for healthcare providers and rein-
forces other previous studies in Tunisia to prevent a fur-
ther spread and in the light of  the current and fabulous 
medical breakthroughs, that we are now witnessing on a 
daily basis of, has to be a wake-up call for us to further 
enhance our efforts and better our practical measures.
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